Avadel Pharmaceuticals: Positioned for Growth with Lumryz and Strategic Acquisitions

Leerink Partners analyst Marc Goodman has maintained their bullish stance on AVDL stock, giving a Buy rating on September 5.

Marc Goodman has given his Buy rating due to a combination of factors influencing Avadel Pharmaceuticals. The company’s once-nightly oxybate product, Lumryz, has been positively received in the market, with expectations for continued growth and increased market share. Although Jazz Pharmaceuticals has managed to protect its Xywav franchise by emphasizing the importance of low sodium for narcolepsy patients with cardiovascular issues, this demographic represents less than 20% of the patient population. Avadel’s potential development of a product that is both once-nightly and low sodium could significantly challenge Jazz’s market position.
Additionally, Avadel’s strategic acquisition of XWPharma’s valiloxybate program, which had previously faced funding and management issues, positions the company favorably. The deal was structured with minimal upfront costs, allowing Avadel to manage it financially. Despite a volatile year, Avadel’s management has addressed previous challenges and demonstrated improved financial performance, suggesting the stock is poised for upward movement as the company continues to meet its financial targets each quarter.

In another report released on September 5, Piper Sandler also reiterated a Buy rating on the stock with a $16.00 price target.